Trending
- Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia
- Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
- When Single-Fraction SRS Still Makes Sense for Resected Brain Metastases
- Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma
- BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
- Genetics and treatment history influence clonal hematopoiesis risk after PARP inhibitor therapy
- SRS Improves Survival Vs Hippocampal Avoidant-WBRT in SCLC Brain Metastases
- Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape
Wednesday, September 30